GILD Gilead Sciences Inc

Price (delayed)

$89.03

Market cap

$111.67B

P/E Ratio

33.34

Dividend/share

$2.9

EPS

$2.67

Enterprise value

$132.19B

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights
Gilead Sciences's debt has decreased by 9% YoY and by 3.8% QoQ
Gilead Sciences's equity has increased by 4.2% from the previous quarter
GILD's P/E is 83% above its last 4 quarters average of 18.2 but 50% below its 5-year quarterly average of 66.7
The company's net income has shrunk by 55% YoY and by 19% QoQ
GILD's EPS has dropped by 55% year-on-year and by 19% since the previous quarter

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$111.67B
Enterprise value
$132.19B
Valuations
Price to earnings (P/E)
33.34
Price to book (P/B)
5.29
Price to sales (P/S)
4.12
EV/EBIT
23.97
EV/EBITDA
17.34
EV/Sales
4.87
Earnings
Revenue
$27.14B
EBIT
$5.51B
EBITDA
$7.62B
Free cash flow
$9.01B
Per share
EPS
$2.67
Free cash flow per share
$7.18
Book value per share
$16.82
Revenue per share
$21.62
TBVPS
$19.76
Balance sheet
Total assets
$62.56B
Total liabilities
$41.5B
Debt
$25.22B
Equity
$21.08B
Working capital
$3.13B
Liquidity
Debt to equity
1.2
Current ratio
1.3
Quick ratio
0.96
Net debt/EBITDA
2.69
Margins
EBITDA margin
28.1%
Gross margin
74.6%
Net margin
12.3%
Operating margin
22.1%
Efficiency
Return on assets
5.2%
Return on equity
16.2%
Return on invested capital
15.2%
Return on capital employed
10.6%
Return on sales
20.3%
Dividend
Dividend yield
3.26%
DPS
$2.9
Payout ratio
108.6%

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
1.29%
1 week
3.21%
1 month
14.32%
1 year
27.79%
YTD
22.61%
QTD
44.32%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$27.14B
Gross profit
$20.25B
Operating income
$6B
Net income
$3.33B
Gross margin
74.6%
Net margin
12.3%
The company's net income has shrunk by 55% YoY and by 19% QoQ
Gilead Sciences's net margin has shrunk by 54% YoY and by 18% QoQ
The operating income has declined by 48% year-on-year and by 14% since the previous quarter
The operating margin has contracted by 48% YoY and by 13% from the previous quarter

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
P/E
33.34
P/B
5.29
P/S
4.12
EV/EBIT
23.97
EV/EBITDA
17.34
EV/Sales
4.87
GILD's P/E is 83% above its last 4 quarters average of 18.2 but 50% below its 5-year quarterly average of 66.7
GILD's EPS has dropped by 55% year-on-year and by 19% since the previous quarter
The stock's price to book (P/B) is 36% more than its last 4 quarters average of 3.9 and 26% more than its 5-year quarterly average of 4.2
Gilead Sciences's equity has increased by 4.2% from the previous quarter
GILD's price to sales (P/S) is 42% more than its last 4 quarters average of 2.9 and 18% more than its 5-year quarterly average of 3.5

Efficiency

How efficient is Gilead Sciences business performance
The company's return on equity has shrunk by 57% YoY and by 19% QoQ
GILD's return on assets has dropped by 52% year-on-year and by 17% since the previous quarter
GILD's return on sales is down by 46% year-on-year and by 15% since the previous quarter
Gilead Sciences's ROIC has decreased by 41% YoY and by 14% from the previous quarter

Dividends

What is GILD's dividend history
DPS
$2.9
Dividend yield
3.26%
Payout ratio
108.6%
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 51% higher than its total liabilities
The total liabilities has contracted by 9% YoY and by 2.7% from the previous quarter
The quick ratio has contracted by 9% from the previous quarter and by 5% YoY
Gilead Sciences's debt is 20% higher than its equity
Gilead Sciences's debt has decreased by 9% YoY and by 3.8% QoQ
The company's debt to equity fell by 8% QoQ and by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.